[1] Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up . Ann Oncol, 2017, 28:iv119-iv142.
[2] Robert C, Long GV, Brady B, Dutriaux C, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015, 372:320-330.
[3] Thompson J A. New NCCN guidelines: recognition and management of immunotherapy-related toxicity . Natl Compr Canc Netw, 2018, 16: 594-596.
[4] Brahmer J R, Lacchetti C, Schneider B J, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline. Clin Oncol, 2018, 36: 1714-1768. |
